Loading...
•
Sep 30, 2021
Pulmonx Q3 2021 Earnings Report
Pulmonx achieved record sales and a gross margin improvement, driven by strong performance in less COVID-impacted geographies.
Key Takeaways
Pulmonx reported a 25% increase in worldwide revenue to $13.3 million for Q3 2021, with a gross margin of 73%. The company is maintaining its full year 2021 revenue guidance in the range of $49 to $51 million.
Worldwide revenue reached $13.3 million, a 25% increase year-over-year.
Gross margin improved to 73% compared to 70% in the same period last year.
Added 18 new U.S. Zephyr® Valve treating centers, bringing the total to 198.
Over 25,000 patients worldwide have been treated with Zephyr® Valves.
Revenue by Geographic Location
Forward Guidance
Pulmonx is maintaining its full year 2021 revenue guidance in the range of $49 to $51 million. The Company expects total operating expenses for the full year 2021 to fall within the range of $83 to $85 million inclusive of stock-based compensation. The Company expects full year 2021 revenue to fall near the low end of this range, representing at least 50% growth over the Company’s full year 2020 revenue.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...